India has surpassed china as the as the choice of medial visit by foreigners and had become the most popular destination for treatment at economical cost.
As per planning commissions report there was 139 cases were registered against 98 of china.
While the market value for clinical trials outsourced to India is estimated at around $300 million, having increased by 65% in 2006, it is expected to touch $1.5-2 billion by 2010.
Factors such as a diverse genetic pool, large patient pool, drug naive population, competent medical professionals, high quality hospitals where trials can be undertaken and low cost of services have stimulated the flow of clinical research to India. The cost of conducting research in India is 20%-60% lower than in developed countries. Savings come from hiring clinical researchers, nurse and IT staff at less than a third of wages in the industrialised countries.
While 20 clinical research organisations and 80 hospitals are engaged in trials, some CROs offer a menu of over 1,500 sophisticated tests under one roof.
The document released by Montek Singh Ahluwalia, however, pointed to one serious shortcoming — India is short by 30,000 to 50,000 research personnel, including trial investigators, auditors, personnel to serve on ethics committees and data safety management boards. The country's regulatory infrastructure has been found to be weak and the office of the Drugs Controller is understaffed.
Accordingto the report of Indian pharmaceuticals alliance there are manycompanies which are dealing with clinical research and they have world class clinics.
For instance the GSK is leading the count with 22 trial cases, after it Johnson and Johnson with 20, eli and lily and BMS with 17 each), Pfizer (16), Sanofi Aventis (15), Astra Zeneac (10), Novartis (9), Merck (8) and Roche (5).
India
